Stock analysis, AI verdict, fundamentals & technical signals
Rating: SELL
Price: $663.49 Analyst target: $651.31 Upside: -1.84%
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
See the full interactive analysis & chart →Informational only — not investment advice.